Background
==========

Over the last decade, there has been a renewed emphasis on research investigating perioperative fluid therapy \[[@B1],[@B2]\]. This has been complemented by a surge in research exploring optimised perioperative care \[[@B3]-[@B5]\]. An increasing body of work has now highlighted the importance of physiologically-guided, individualised fluid administration in keeping with the broad principles recommended by Moore and Shires over 40 years ago \[[@B6],[@B7]\]. This concept is known as goal--directed fluid therapy (GDFT).

GDFT therapy primarily involves the administration of intravenous fluids to optimise pre-defined, patient-specific clinical proxies of tissue perfusion \[[@B7]\]. The individual parameters used to guide therapy are measures of cardiovascular function and vary depending on the monitoring system used \[[@B7]\]. In practice, GDFT involves repeated administration of small boluses of intravenous fluids- often colloids- until a certain target or plateau is reached. A baseline infusion of crystalloids is typically given.

A number of randomised trials and subsequent meta-analyses in various surgical settings have shown that GDFT confers clinical benefits such as decreased postoperative morbidity and decreased hospital length of stay as compared to traditional, liberal fluid therapy \[[@B8]-[@B14]\]. This is thought to be on the basis of treating occult hypovolaemia, preventing fluid overload or correcting a preoperative functional intravascular deficit early in the intraoperative phase to decrease the post-surgical inflammatory response \[[@B9]-[@B11]\]. The National Institute for Health Research and the Health Technology Assessment committee in the United Kingdom (UK) found in their systematic review that GDFT using the Oesophageal Doppler Monitor (ODM) provides clinical benefits in major surgery and is cost effective \[[@B15]\]. The National Health Service Centre for Evidence-based Purchasing also concluded that the cost of the ODM would be offset by the clinical benefits seen \[[@B16]\]. The use of GDFT tools is also reimbursed in the United States of America (USA) by the Center for Medicare and Medicaid Services who have stated that the use of the Oesophageal Doppler Monitor (ODM) is both "reasonable and necessary" for operative patients requiring fluid optimisation \[[@B17],[@B18]\]. As a result, a number of guidelines from professional groups have recommended the use of GDFT in major surgery in selected cases \[[@B19],[@B20]\].

However, some authors have expressed reservations regarding the proposed benefits of GDFT for all patients. The criticisms include a paucity of trials within an optimised perioperative care environment and no comparison to intraoperative fluid restriction, which is also recognised as beneficial in a similar cohort of patients \[[@B2],[@B14],[@B21],[@B22]\]. A recent qualitative review has also outlined several important unanswered questions in the context of GDFT in colorectal surgery \[[@B23]\]. Moreover, questions persist regarding the best monitoring system, the ideal intraoperative fluid and clinical situations when GDFT is appropriate \[[@B7],[@B23],[@B24]\]. Therefore, there is clinical and academic equipoise regarding the proposed benefits or otherwise of GDFT.

For those in favour of GDFT, the translation of evidence into practice can be a significant hurdle \[[@B25],[@B26]\]. Clinical benefits necessitate proven interventions to be suitably implemented. Selective implementation of interventions can often fail to replicate the benefits observed in trials \[[@B25]\]. It is thus important to assess the current practice and attitudes of clinicians and to identify barriers that may prevent the implementation of evidence-based practice \[[@B26],[@B27]\]. Therefore, we conducted a survey of anaesthetists nationally and internationally to investigate various characteristics regarding GDFT across Australasia, the United Kingdom (UK) and the USA. Specific aims included examining the disparity in clinical uptake of GDFT, situations within which it was used and the preferred tools as well as the barriers to adoption of this technique.

Methods
=======

Ethical approval was obtained from the Northern X Regional Ethics Committee (NTX/10/EXP/147). An electronic survey was created using a commercially available internet-based service \[[@B28]\]. The survey was administered electronically to 2000 randomly chosen members of the Association of Anaesthetists of Great Britain and Ireland (AAGBI), 2000 randomly chosen members of the American Society of Anesthesiology (ASA) and to 500 randomly chosen members of the Australia and New Zealand College of Anaesthetists (ANZCA) as per the conditions stipulated by each organisation. Randomisation and survey admitration was facilitated by the individual member organisations with respondents remaining anonymous to the investigators. One reminder was sent to the non-responders 4 weeks after the first invitation. The questions from the survey are presented in Table  [1](#T1){ref-type="table"}. Results were subsequently collated and the two-tailed Fisher's exact test was used to assess categorical outcomes. A p value of less than 0.05 was considered statistically significant.

###### 

Survey questions

  **Questions**                                                                                                             **Options**
  ------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Which country do you work in?                                                                                              
  What is your place of practice? (choose as many as applicable)                                                            Tertiary Hospital/District (Community) Hospital/Private practice
  What is your subspecialty interest? (up to three choices)                                                                 Abdominal Surgery/Non-abdominal general surgery/Orthopaedic surgery/Urology/Cardiothoracic surgery/Obstetrics/Gynaecology/Vascular Surgery/Neurosurgery/Otorhinolaryngology/Ophthalmology/Plastic Surgery/Paediatric Surgery/Trauma/Burns
  What is your current position?                                                                                            Trainee/Consultant \< 5 years/Consultant 5--10 years/Consultant \> 10 years
  **For adult patients having major elective surgery...**                                                                   
  What is your preferred intraoperative crystalloid fluid?                                                                  Normal saline/Balanced salt solution/Dextrose saline/No preference
  What is your preferred intraoperative colloid fluid?                                                                      Succinylated gelatin/Tetrastarch/Pentastarch/Hetastarch/Albumin/Nil/No preference/Other
  What is your preferred intraoperative pressor? (please state type)                                                         
  For adult patients undergoing major elective surgery, do you use goal-directed fluid therapy?                             Always/Sometimes/Never
  If you use goal directed fluid therapy sometimes, when? (Choose as many as applicable)                                    Major surgery/Patients with significant comorbidities/Particular operations (state type)/Depending on Instrument availability/Random/Other
  If yes, what kind of surgery do you use goal directed fluid therapy in? (choose as many as applicable)                    Abdominal Surgery/Non-abdominal general surgery/Orthopaedic surgery/Urology/Cardiothoracic surgery/Obstetrics/Gynaecology/Vascular Surgery/Neurosurgery/Otorhinolaryngology/Ophthalmology/Plastic Surgery/Paediatric Surgery/Trauma/Burns
  What are your preferred tools to conduct Goal Directed Fluid Therapy? (choose up to 3)                                    ODM/PPV monitors/SVV monitors/LiDCO/PAC/SvO2/PVI
  If you never use goal directed fluid therapy, why? (choose as many as applicable)                                         Lack of resources/Nil advantage perceived/Too labour intensive/Unsuitable patients/Lack of experience with instruments
  If existing barriers were removed (e.g. lack of resources/training), would you like to use Goal Directed Fluid Therapy?   Yes/No/Undecided

*ODM*: Oesophageal Doppler monitor; *PPV*: Pulse pressure variation; *SVV*: Stroke volume variation; *LiDCO*: Lithium dilution coefficient; *PAC*: Pulmonary artery catheter; *SvO2*: Venous oxygen saturations; *PVI*: Pleth variability index.

Results
=======

The demographic characteristics of respondents and the response rates are presented in Table  [2](#T2){ref-type="table"}. The response rates in the UK and AUS/NZ were 35% and 36% respectively. The response rate in the USA was 9%, thereby limiting the validity of any deductions from these data. Amongst responders, the survey completion rate was high across all three regions (UK: 94%; AUS/NZ: 89%). The two commonest subspecialty interests were orthopaedic surgery (AUS/NZ: 76 (46%); UK: 240 (37%)) and abdominal surgery (AUS/NZ: 71(43%); UK: 300 (46%)). Intraoperative fluid preferences are as per Table  [3](#T3){ref-type="table"}. The two most favoured pressors in the UK and AUS/NZ were metaraminol (UK: 281 (42%); AUS/NZ: 102 (59%)) and phenylephrine (UK: 142 (22%); AUS/NZ: 36 (21%)).

###### 

Respondent characteristics

                                            **AUS/NZ**   **UK**     **p-value\***
  ----------------------------------------- ------------ ---------- ---------------
  **No of responders (%)**                  180          708         
  **Response rate**                         36%          35%         
  **Place of practice (%):**                                         
  **Tertiary Hospital District Hospital**   122 (69)     360 (51)   \<0.01
  **Private Practice**                      34 (19)      377 (54)   \<0.01
  68 (38)                                   89 (13)      \<0.01     
  **Experience (%):**                                                
  **Trainee**                               2 (1)        168 (24)   \<0.01
  **Consultant \<5 years**                  27 (15)      161 (23)   0.02
  **Consultant 6--10 years**                28 (16)      98 (14)    0.63
  **Consultant \>10 years**                                          
                                            122 (68)     269 (39)   \<0.01

\*Two-tailed Fisher's exact test.

###### 

Intraoperative fluid preferences

                           **AUS/NZ**   **UK**
  ------------------------ ------------ ----------
  Crystalloid (%)          n = 174      n = 692
  0.9% Saline              10 (6)       14 (2)
  Balanced Salt Solution   162 (93)     662 (96)
  Colloid (%)                            
  Succinylated gelatine    43 (24)      292 (42)
  Tetrastarch              30 (17)      98 (14)
  Pentastarch              29 (16)      50 (7)
  Hetastarch               29 (16)      124 (18)
  Albumin                  14 (8)       1
  No preference            26 (15)      98 (14)
  Other                    8 (4)        29 (4)

The use of GDFT is shown in Figure  [1](#F1){ref-type="fig"}. GDFT use was significantly more common in the UK as compared to AUS/NZ (p \< 0.01). In AUS/NZ, GDFT was most commonly utilised in abdominal surgery (n = 60; 80%), followed by orthopaedic surgery (n = 27; 36%). In the UK, GDFT was most commonly utilised in abdominal surgery (UK: n = 428 (89%)), followed by vascular surgery (UK: n = 146 (30%)).

![**Do you use Goal-directed fluid therapy? (Columns from left to right respectively: Always; Sometimes; Never).** Always/Sometimes: USA vs. UK, p = 0.36; USA vs. NZ, p \< 0.01; UK vs. NZ, p \< 0.01.](1471-2253-13-5-1){#F1}

The situations when GDFT is utilised and preferred tools to conduct GDFT are shown in Tables  [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"} respectively. The commonest reasons stated for not using GDFT were either lack of availability of monitoring tools (AUS/NZ: 57 (70%); UK: 94 (64%)) or a lack of experience with instruments (AUS/NZ:43 (53%); UK: 51 (35%)). A subset of respondents cited "nil advantage perceived" as the reason for not using GDFT (AUS/NZ: 22(27%); UK: 45 (30%)). Enthusiasm towards GDFT in the absence of existing barriers (e.g. lack of equipment or experience) is shown in Figure  [2](#F2){ref-type="fig"}.

###### 

Situations when goal-directed fluid therapy is used

  **Indication (%)**          **AUS/NZ (n = 87)**   **UK (n = 523)**
  --------------------------- --------------------- ------------------
  Major Surgery               50 (69)               326 (73)
  Significant Comorbidities   51 (70)               367 (83)
  Specific Operations         20 (27)               107 (24)
  Instrument availability     19 (26)               125 (28)
  Random                      0                     11 (3)

###### 

Preferred tools for goal-directed fluid therapy

  **Tools (%)**   **AUS/NZ (n = 78)**   **UK (n = 519)**
  --------------- --------------------- ------------------
  ODM             11 (19)               362 (76)
  PPV             26 (45)               97 (20)
  SVV             21 (36)               71 (15)
  LiDCO           1 (2)                 93 (20)
  PAC             17 (29)               35 (7)
  SvO2            12 (21)               88 (19)
  PVI             3 (5)                 8 (2)

*ODM*: Oesophageal doppler monitor; *PPV*: Pulse pressure variation; *SVV*: Stroke volume variation; *LiDCO*: Lithium dilution coefficient; *PAC*: Pulmonary artery catheter; *SvO2*: Venous oxygen saturation; *PVI*: Pleth variability index.

![Would you like to use Goal-Directed Fluid Therapy? (Columns from left to right respectively: Yes/No/Undecided).](1471-2253-13-5-2){#F2}

The respondents from the USA indicated a preference towards GDFT in abdominal surgery (n = 97; 80%) with similar barriers to GDFT as described in other regions such as lack of availability of tools (n = 19; 59%), lack of experience (n = 13; 40%) and nil perceived advantage (n = 13; 40%). The most favoured pressor in the USA was phenylephrine (68; 40%), followed by ephedrine (41; 24%).

Discussion
==========

This survey of 1067 anaesthetists from the UK, AUS/NZ and the USA reveals important differences in practice with regards to intraoperative fluid therapy and GDFT specifically. The response rates were moderate or low, especially in the USA, and it is likely that the present data represents views of a self-selected group among the anaesthetists who were randomly invited to participate. Such selection could be based on strong positive or negative views on GDFT. Nevertheless, certain observations can be made and hypotheses generated regarding the interest in and barriers to GDFT in the UK and AUS/NZ. The poor response rate from the USA limits the validity of any statements regarding practice in this region except to speculate that there is comparatively lesser interest in this topic.

The use of GDFT seems to be significantly less prevalent in AUS/NZ compared to the UK amongst respondents in this survey. The majority of the respondents were involved in major abdominal surgery and orthopaedic surgery and used GDFT in patients with significant comorbidities. The ODM is the most commonly utilised instrument in the UK with significant variation in preferences in other regions. The most significant barriers to conducting GDFT were either a lack of availability of monitoring tools or a lack of experience with instruments. Even though a proportion of respondents from all regions remain unconvinced of the benefits of GDFT, there was significant enthusiasm overall towards trialling GDFT if barriers were to be removed.

The use of GDFT was most common in the UK which may have been made possible by governmental endorsement and funding of the ODM specifically with demonstrated cost-effectiveness \[[@B15],[@B16]\]. Nationally-driven implementation may also potentially overcome the problems associated with silo budgeting as GDFT represents an anaesthetic intervention- thereby adding cost to clinical departments of anaesthesia- to provide financial benefits for surgical services such as decreased hospital length of stay. This represents a potential blueprint for other regions to follow. For clinicians, the recently published GIFTASUP guidelines which recommend mandatory use of GDFT in major abdominal surgery may have also provided further impetus \[[@B20]\].

Moreover, a significant portion of the evidence supporting GDFT originates from the UK \[[@B9],[@B11],[@B29]\]. The recent guidelines from the European Enhanced Recovery After Surgery (ERAS) group have also shown enthusiasm towards GDFT and the ODM and, as ERAS protocols are instituted across the UK, GDFT has been integrated into practice as well \[[@B19],[@B30],[@B31]\]. This has likely led to the emergence of the ODM as the preferred tool to conduct GDFT in the UK. In contrast, the principles of optimised perioperative care have shown reduced penetrance in AUS/NZ with persisting scepticism regarding benefits \[[@B32],[@B33]\]. In AUS/NZ, there appears to be no clear preference with regards to tools for GDFT.

The barriers identified to the use of GDFT appear eminently solvable especially if the observed benefits from trials are replicated in clinical practice \[[@B13]\]. Many of the instruments used to conduct GDFT are simple to use and the learning curve for the ODM can be overcome after 12 insertions \[[@B34]\]. However, it should be noted that in the context of abdominal surgery, restrictive fluid regimens have also shown similar benefits to GDFT and the majority of the trials investigating GDFT have not been conducted in an environment of standardised, optimised perioperative care \[[@B14],[@B23]\].

A proportion of people from all the regions surveyed remain sceptical regarding the proposed benefits of GDFT. To an extent, this is justified as important questions remain unanswered, such as efficacy in settings where fluid restriction has been shown to be beneficial \[[@B21]-[@B23]\]. Nonetheless, it is interesting to note that in the absence of barriers, a high proportion of respondents would be willing to consider GDFT into their practice. This suggests that future randomised trials or selective clinical implementation of GDFT remain feasible and are required.

Whilst the use of intraoperative crystalloids was largely homogeneous between the regions, there were interesting differences in practice between the three regions with regards to colloid use. There are considerable differences between individual classes of colloids as well as between the individual colloid products themselves \[[@B35],[@B36]\]. Succinylated gelatin solutions were favoured in the UK and AUS/NZ with the latter showing a wide variation in practice. This may be a reflection of the variable availability and cost of these solutions.

There are important limitations to this study which need to be considered alongside the results. The survey was designed on the basis of questions of clinical importance but was not developed with a focus group nor with redundant questions to validate its methodology. Moreover, since the survey aimed towards an overview of GDFT, specifics could not be elucidated regarding any one aspect (e.g. specific barriers). Any barriers identified were the opinion of the respondent and may not be reflective of the institution or the region in its entirety. The number of individuals to be surveyed was limited by the respective professional associations. The colleges facilitated selection of individuals with no author input allowed regarding this. The only selection criterion was to prevent administration of the survey to individuals who had previously replied to other college-led surveys to minimise responder fatigue. In the context of a low-moderate response rate, it cannot be assumed with certainty that it is representative of the anaesthetic community in its entirety.

Conclusion
==========

There are important differences in fluid administration and the use of GDFT between anaesthetists from the UK and AUS/NZ. The identified barriers can potentially be overcome and though some clinicians remain unconvinced, there is significant interest in utilising GDFT in clinical practice. Future directions from this work can include selective implementation of GDFT or further clinical studies.
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